Ultragenyx

halfway there
Biotech

Ultragenyx gene therapy lessens ammonia levels in ph. 3

One-time treatment with DTX301 led to 18% lower ammonia levels compared to placebo at 36 weeks, hitting one of the trial's two key endpoints.
Darren Incorvaia Mar 12, 2026 11:33am
layoffs employees crossed off

Ultragenyx lays off 10% of workers as FDA stalls approval plan

Feb 13, 2026 3:01am
Darts failing to hit bullseye

2025's top 10 clinical trial flops

Feb 9, 2026 3:00am
Golfer devastated after just barely missing a putt

Ultragenyx plans cost-cutting push after flunking phase 3 trials

Jan 2, 2026 5:37am
FDA

FDA plans real-time release of drug rejection letters

Sep 4, 2025 1:45pm
FDA stop sign
Favicon Fierce Pharma

FDA snubs Ultragenyx gene therapy over manufacturing issues

Jul 14, 2025 10:16am